enGene (NASDAQ:ENGN) Trading Up 4.6% - What's Next?

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) shares shot up 4.6% during trading on Tuesday . The company traded as high as $9.06 and last traded at $9.1760. 4,166 shares traded hands during trading, a decline of 99% from the average session volume of 403,350 shares. The stock had previously closed at $8.77.Wall Street Analysts Forecast GrowthSeveral analysts have recently weighed in on ENGN shares. HC Wainwright reissued a "buy" rating and set a $25.00 price objective on shares of enGene in a report on Wednesday, December 3rd. UBS Group raised their price objective on shares of enGene from $4.00 to $10.00 and gave the stock a "neutral" rating in a report on Wednesday, November 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of enGene in a research report on Tuesday, October 14th. Citigroup reissued a "market outperform" rating on shares of enGene in a research report on Wednesday, November 12th. Finally, Raymond James Financial raised enGene from an "outperform" rating to a "strong-buy" rating and set a $27.00 price objective on the stock in a report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, enGene presently has an average rating of "Moderate Buy" and a consensus price target of $22.38.View Our Latest Report on ENGNenGene Stock PerformanceThe firm has a market capitalization of $592.20 million, a P/E ratio of -4.83 and a beta of -0.28. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.34 and a quick ratio of 10.34. The stock's 50 day moving average is $7.89 and its two-hundred day moving average is $5.79. enGene (NASDAQ:ENGN - Get Free Report) last posted its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.18). As a group, equities analysts anticipate that enGene Holdings Inc. will post -1.56 earnings per share for the current fiscal year. Institutional Trading of enGeneSeveral hedge funds have recently added to or reduced their stakes in ENGN. Braidwell LP acquired a new position in shares of enGene in the 3rd quarter valued at approximately $15,479,000. Adage Capital Partners GP L.L.C. lifted its position in enGene by 2.7% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company's stock valued at $7,041,000 after acquiring an additional 41,874 shares in the last quarter. MAI Capital Management boosted its stake in enGene by 11.0% in the 1st quarter. MAI Capital Management now owns 78,067 shares of the company's stock worth $350,000 after purchasing an additional 7,756 shares during the period. Affinity Asset Advisors LLC bought a new position in enGene during the 2nd quarter worth about $280,000. Finally, Citadel Advisors LLC lifted its holdings in shares of enGene by 153.3% in the third quarter. Citadel Advisors LLC now owns 58,370 shares of the company's stock valued at $399,000 after purchasing an additional 35,327 shares in the last quarter. Institutional investors and hedge funds own 64.16% of the company's stock. enGene Company Profile (Get Free Report)enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity. Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.Read MoreFive stocks we like better than enGeneDo not delete, read immediatelyINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffElon Warns “America Is Broke”. Trump’s Plan Inside.Can Any Expenses Be Deducted From Capital Gains Tax?Buffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in enGene Right Now?Before you consider enGene, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.While enGene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here